NFκB p65 Monoclonal Antibody (ABM40111): Cutting Through the Noise in NF-κB Pathway Research

The NF-κB p65 Problem: Smears, Cross-Reactivity, and Batch Variability

The NF-κB pathway sits at the heart of immune defense, chronic inflammation, and cancer. At its center is p65 (RelA), the transactivating subunit that turns gene expression on or off[reference:5]. But studying p65 isn't just about having an antibody—it's about having one that works, every time.

Researchers face familiar roadblocks: cross-reactivity with other Rel family members (p50, c-Rel) that muddies Western blots, weak signals in low-expression cells, and batch-to-batch variability that can derail months of work[reference:6].

Abbkine's NFκB p65 Monoclonal Antibody (ABM40111) was built to solve these exact problems.

Monoclonal Precision: The IgG1 Advantage

ABM40111 is a mouse-derived IgG1 monoclonal raised against a recombinant human p65 fragment spanning amino acids 1–300 (the N-terminal transactivation domain)—a region less prone to post-translational modification interference[reference:7]. No more worrying about false positives from related proteins: it's been validated with knockout cell line controls (p65-/- HEK293T) to prove it binds only to p65[reference:8].

Certificate of Analysis: Batch Consistency You Can Verify

Many brands skip batch testing, but Abbkine's ABM40111 ships with a certificate of analysis (CoA) showing titer consistency across three consecutive lots, with <5% variation in EC50 values for Western blots[reference:9]. For longitudinal studies or cross-lab collaborations, this level of documentation is game-changing.

Multi-Application Versatility

Specifications at a Glance

The Bottom Line

For immunology, oncology, or cell signaling researchers, ABM40111 delivers the reproducibility, specificity, and validation data needed for publication-ready NF-κB research.

📎 Reference: NFkB p65 Monoclonal Antibody (ABM40111)